



# WORLD'S LEADING MANUFACTURER OF A WIDE RANGE OF APIs

---



---

API PRODUCT LIST

## API PRODUCT LIST

Product	Category	Regulatory Filings		
		US-DMF #	CEP	ADDITIONAL FILINGS
Amiodarone Hydrochloride	Anti-arrhythmic	021694	✓	
Anagrelide	Platelet Reducing Agent	038181		
Aprepitant	Anti-emetic	026065	✓	
Azilsartan Kamedoxomil	Anti-hypersentives	035770		
Baclofen	Muscle Relaxant	028455	✓	TDMF
Bisoprolol Fumarate	Anti-hypertensive	029123	✓	
Cinacalcet Hydrochloride	Calcimimetic	029162		TDMF
Clobazam	Anti-convulsant	029164		
dl-Cloprostenol*	Luteolytic Agent	015758		
Dabigatran Etexilate Mesylate	Anti-coagulant	030404	Filed	
Dapagliflozin Propanediol Monohydrate	Anti-diabetic	033282		KDMF
Deferasirox	Iron Chelator	031485		
Dexlansoprazole	Anti-ulcerant	033685		
Diltiazem Hydrochloride	Anti-hypertensive	014713	✓	JDMF, KDMF
Donepezil Hydrochloride	Anti-alzheimer's	027650		
Dronedarone Hydrochloride	Anti-arrhythmic	031486		
Droxidopa	Anti-parkinson	034258		
Empagliflozin	Anti-diabetic	033545		
Fosaprepitant Dimeglumine	Anti-emetic	031484		JDMF, KDMF, CDMF
Ketoconazole	Anti-fungal	017290	✓	Canadian DMF, JDMF, CDMF, KDMF, TDMF
Lercanidipine	Anti-hypertensive			
Levoketoconazole	Cushing's Syndrome	038973		
Lurasidone Hydrochloride	Anti-psychotic	029163		Canadian DMF
Mebeverine Hydrochloride	Anti-spasmodic		✓	TDMF
Mirabegron	Urinary Incontinence	033281	Filed	
Misoprostol	Anti-ulcerant	021188	✓	
Monusulfiram	Ectoparasiticide			
Pramipexole Dihydrochloride Monohydrate	Anti-parkinson	030186	✓	
Rivaroxaban	Anti-coagulant	030403		
Spirolactone	Diuretic		✓	
Tetrabenazene	Hyperkinetic Movement Disorder	032450		
Trazodone Hydrochloride	Anti-depressant	020920	✓	Canadian DMF, CADIFA, CDMF, KDMF, TDMF
Varenicline Tartrate	Nicotinic Antagonist	034116		
Verapamil Hydrochloride	Anti-hypertensive	016605	✓	Canadian DMF, CADIFA, TDMF, CDMF
Vortioxetine Hydrobromide	Anti-depressant	035801		

## APIs (UNDER DEVELOPMENT)

Product	CAS No.
Apremilast	608141-41-9
Bilastine	202189-78-4
Brivaracetam	357336-20-0
Desvenlafaxine Succinate Monohydrate	386750-22-7
Dexmedetomidine	145108-58-3
Edoxaban	1229194-11-9

\* Veterinary Drug      ✓ CEP Approved

All subject to the disclaimer on the last page.



## PEPTIDE API PRODUCT LIST

Product	Regulatory Filings		
	US-DMF	CEP	ADDITIONAL FILINGS
Buserelin Acetate*		✓	
Calcitonin Salmon Acetate		✓	
Carbetocin Acetate			EU-ASMF
Cetrorelix Acetate	034552		EU-ASMF
Desmopressin Acetate	022871	✓	KDMF, Canadian DMF
Gonadorelin Acetate*			
Leuprorelin Acetate	025128	✓	KDMF
Octreotide Acetate	036322		
Oxytocin Acetate*	037689	✓	US-VMF
Oxytocin conc. Solution			EU-ASMF
Terlipressin Acetate		✓	KDMF, EU-ASMF
Tetracosactide Acetate			
Vasopressin Acetate	032146		


## PEPTIDE APIs (UNDER DEVELOPMENT)

Product	CAS No.
Abaloparatide Acetate	247062-33-5
Atosiban Acetate	914453-95-5
Corticotropin Acetate	12427-33-7
Glatiramer Acetate	386750-22-7
Glucagon Acetate	16941-32-5
Lanreotide Acetate	127984-74
Linaclotide Acetate	851199-60-5
Liraglutide Acetate	204656-20-2
Plecanatide Acetate	467426-54-6
Semaglutide Acetate	910463-68-2
Teduglutide Acetate	197922-42-2
Triptorelin Acetate	140194-24-7

\* Veterinary Drug    ✓ CEP Approved

All subject to the disclaimer on the last page.

## OUR ESG FRAMEWORK



**Operating Responsibly, Growing Sustainably**

## OUR KEY ESG TARGETS

- Reduce Carbon Footprint: Reduce Scope 1 and Scope 2 emission by 42% by FY2030 (against the baseline of FY2022) – in-line with 1.5 degree pathway suggested by SBTi
- Committed to reduce Scope 3 emissions by 25% by 2030 (with base line of FY 2022) in line with 2.0 degrees trajectory
- Waste Management: Achieve zero hazardous waste to landfill by FY2025
- Water Conservation: Withdrawal reduction potential of 400 KLD of fresh water at India sites identified through Comprehensive Water use Assessment study. Initiatives underway
- Responsible Supply Chain: Assess 70% of critical suppliers by FY2026
- Gender Diversity: Achieve 16% women in the workforce globally by FY2025
- Employee Safety: Maintain LTIR < 0.2 per 200,000 person-days worked

# OUR FACILITIES



**MORPETH, UK**  
API & FORMULATION  
DEVELOPMENT &  
MANUFACTURING  
USFDA, MHRA



**GRANGEMOUTH, UK**  
ADC DEVELOPMENT  
& MANUFACTURING  
USFDA, MHRA



**DIGWAL, INDIA**  
API DEVELOPMENT  
& MANUFACTURING  
USFDA, MHRA



**ENNORE, INDIA**  
API DEVELOPMENT  
& MANUFACTURING  
WHO, GMP




**TURBHE, INDIA**  
PEPTIDE API  
DEVELOPMENT  
& MANUFACTURING  
USFDA



**THANE, INDIA**  
PEPTIDE R&D



**RABALE**  
API DEVELOPMENT



32024



**Piramal Pharma Solutions**  
Agastya Corporate Park, Kamani Junction,  
Kurla (West), Mumbai 400 070 India  
[generics.api@piramal.com](mailto:generics.api@piramal.com)



Just scan the QR Code to  
download this brochure.

[piramalphasolutions.com](http://piramalphasolutions.com)

Piramal Enterprises Limited (Company) does not offer or supply for commercial use, Products protected under valid patents, where the sale of such products constitutes a patent infringement. Only research & development quantities of such products are manufactured and offered for the purpose of regulatory submissions in India and/or other jurisdiction, wherever such regulatory exemptions exist, according to Section 107A of the Indian Patent Act and the corresponding provision of the Patent Act of the respective jurisdiction. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Piramal makes no warranty as to the completeness or accuracy of the information provided herein. Furthermore, no information in this catalogue - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. In particular, nothing in this catalogue should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.